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Abstract
Children with severe acute malnutrition (SAM) with complications require in-patient management including therapeutic feeding. Little
attention has been given to the effects of these feeds on the essential fatty acid status of children with SAM. The objective of this study was to
describe changes in the PUFA composition in whole blood in children with SAM during treatment and to determine predictors of change. This
prospective study took place in a paediatric nutrition rehabilitation unit in Kampala, Uganda, and assessed whole-blood fatty acid composition
of children with SAM at admission, transition, discharge and follow-up (8 and 16 weeks). ANCOVA was used to identify predictors of change
in whole-blood PUFA. The study included 120 children with SAM and twenty-nine healthy control children of similar age and sex. Among the
SAM children, 38% were female and 64% had oedema. Whole-blood n-6 PUFA proportions increased from admission to follow-up, except for
arachidonic acid, which decreased by 0·79 (95% CI 0·46, 1·12) fatty acid percentage (FA%) from admission to transition and 0·10 (95% CI 0·23,
0·44) FA% at discharge. n-3 Long-chain (LC) PUFA decreased by 0·21 (95% CI 0·03, 0·40) FA% at discharge and 0·22 (95% CI 0·01, 0·42) FA%
at 8 weeks of follow-up. This decrease was greater in children from families with recent fish intake and those with nasogastric tube feeding.
Current therapeutic feeds do not correct whole-blood levels of LCPUFA, particularly n-3 LCPUFA, in children with SAM. Increased attention is
needed to the contents of n-3 LCPUFA in therapeutic feeds.
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Severe acute malnutrition (SAM) is a major health problem
in children in low-income and middle-income countries(1).
Children with complicated SAM require in-patient management
of presenting complications while therapeutic feeds are being
initiated. The standard nutritional treatment is milk-based
formulas, such as starter F-75, initiated as soon as possible
after admission(2). F-75 is designed to restore physiological and
metabolic functions and electrolyte balance and to maintain
body weight. After stabilisation, the feed is gradually changed to
a formula (F-100) that provides sufficient energy and protein to
support rapid catch-up growth or directly to ready-to-use
therapeutic feed (RUTF)(3). RUTF is typically continued after
discharge and given at regular follow-ups until recovery.
An average period of 8 weeks of nutritional rehabilitation is
considered adequate for recovery(4), after which good feeding
practices are encouraged. During rehabilitation of children with
SAM, emphasis is put on adequate intake of energy and protein,
as well as on micronutrients, whereas PUFA intake is given less
attention.
Fatty acids are good sources of energy. However, effects of
n-3 and n-6 fatty acids go far beyond their role as fuels, as they
are essential nutrients with important physiological functions.
The n-6 PUFA linoleic acid (LA, 18 : 2n-6) is incorporated in skin
ceramides, whereas arachidonic acid (AA, 20 : 4n-6) in cell
membranes acts as a precursor of eicosanoid(5). A deficiency in
these fatty acids can therefore result in scaly skin, reduced
growth and increased infections among others. The main
function of n-3 PUFA is exerted via DHA (22 : 6n-3) in central
nervous system membranes, where they have a structural role,
as well as a role in functional processes that are not completely
clarified(5). A lack of essential n-6 and n-3 fatty acids will result
in increased production of Mead acid (20 : 3n-9) and n-6
docosapentanoic acid (DPA) (22 : 5n-6), the metabolical
counter parts of AA and DHA, respectively, that do not fulfil
Abbreviations: AA, arachidonic acid; ALA, α-linolenic acid; DPA, docosapentanoic acid; %E, percentage of energy intake; FA%, fatty acid percentage;
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their essential functions. These two fatty acids may therefore
indicate n-3 and n-6 deficiency, sometimes reported as ratios
with their respective n-6 and n-3 fatty acid counterparts.
A number of studies show associations between SAM and a
low n-3 and n-6 PUFA status(6). However, limited data exist on
the effect of recovery from SAM on LA, α-linolenic acid (ALA,
18 : 3n-3) and long-chain (LC) PUFA status (LCPUFA defined as
PUFA with >18 carbon atoms and >3 double bonds). A study of
Nigerian hospitalised children with SAM found significant
increases in LA values and decreases in AA values after 2 weeks
of treatment with a therapeutic high-energy and high-protein
diet with maize and milk, eggs, beans, vegetables, fish, meat,
vegetable and palm oil(7). ALA values did not change during
hospitalisation, but the DHA content of plasma phospholipids
increased significantly(7). A recent study of Kenyan children
with SAM found that n-3 and n-6 PUFA requirements of
children with SAM were not met by the current formulation of
RUTF or by a RUTF with elevated levels of ALA but without n-3
LCPUFA(8). Another study of Malawian children with SAM
compared standard RUTF with a novel RUTF with relatively less
LA and more oleic acid (HO-RUTF) to children and found
positive changes in plasma phospholipid DHA and EPA
(20 : 5n-3) in the HO-RUTF group compared with the RUTF
group(9). No studies have investigated the effects of F-75 and
F-100 during in-hospital treatment of SAM on children’s fatty
acid status.
This prospective study investigates changes in whole-blood
PUFA in Ugandan children with SAM from hospital admission to
transition, discharge and follow-up after 8 and 16 weeks. We
furthermore describe associations between changes in whole-
blood PUFA values and clinical conditions during treatment.
Methods
Study design, site and standard treatment
This prospective observational study followed up children with
in-hospital treatment of SAM between October 2012 and
June 2013.
Mwanamugimu Nutrition Unit at Mulago Hospital is the main
treatment centre for children with complicated SAM in Uganda.
Children received standard in-patient treatment according to the
Ugandan National Protocol for the Integrated Management of
Acute Malnutrition(10), based on recommendations from the
World Health Organization(11). Children were given therapeutic
diets, F-75 and F-100 (Nutriset) and empirical parenteral anti-
biotics, usually ampicillin and gentamicin. Small, frequent feeds
of F-75 were given at a rate of 100–130ml/kg body weight per
d, either orally or by the nasogastric (NG) tube. After stabilisa-
tion, the children were changed from F-75 to catch-up milk-
based formula F-100(2). After about 2–3 d of transition, the
volume of F-100 was gradually increased to a maximum of
220ml/kg per d. When the children were clinically well, had
regained appetite and had no oedema, they were discharged
for out-patient treatment with RUTF. The children were then
followed up in the hospital’s out-patient clinic every 2 weeks
until recovery from SAM, as indicated by 20% weight gain, no
oedema for two consecutive follow-up visits and increasing
mid-upper arm circumference (MUAC) according to recommen-
dations at the time of study(12). Biological mothers were offered
routine counselling and testing for HIV antibodies according to
WHO guidelines, using DetermineTM rapid test as first-line(13). If
the mother was infected or absent, the child was tested.
A few local modifications of the protocol were practiced
at the time of the study: if a child had diarrhoea and milk
intolerance was suspected, the diet was fully or partially
replaced by rice porridge for some days. Furthermore, most
children were given a daily serving of maize-soya-porridge
during and after the transition phase, and these maize-soya-
based products’ composition varied. In preparation for
discharge, all mothers participated in cooking classes preparing
energy-dense complementary foods using locally available
ingredients, which was also served to the children.
Selection criteria
Children 6–59 months of age with SAM, defined as weight-
for-height z-score (WHZ)<− 3 of the WHO Growth Standard,
MUAC<11·5 cm or bilateral pitting oedema, and who lived near
the hospital were eligible for the study. Those who were in
shock at admission, had severe respiratory distress requiring
resuscitation, Hb concentration<4 g/dl, body weight<4·5 kg or
significant disability such as cerebral palsy were excluded.
Inclusion was not possible during weekends or public holidays.
A control group of healthy well-nourished children was
recruited among siblings of the admitted children and children
of hospital staff. The inclusion criteria for these children were
being apparently healthy, aged 6–59 months old and having a
WHZ>− 1.
Sample size
The sample size of 120 was based on the main outcome, plasma
phosphate(14). With 120 SAM children, we would have 80%
power to detect a difference of 0·5 SD or more in any normally
distributed variable between two groups of equal size, with a
5% significance level. Similarly, with a control group of thirty
children, we would have 80% power to detect differences of 0·6
SD or more between SAM and control.
Ethical issues
Approval of the study was obtained from the Makerere
University School of Medicine Research Ethics Committee, and
Uganda National Council of Science and Technology, and a
consultative approval was obtained from the Danish National
Board of Research Ethics. Informed consent was provided by
parents or guardians of the children before enrolment into the
study. Regardless of participation in the study, all children
admitted with SAM received similar routine medical and
nutritional treatment.
Data collection
A questionnaire was used to obtain socio-demographic infor-
mation, as well as feeding and medical history. Physical
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examination including vital signs and checking of bilateral
pitting oedema was performed. Anthropometric measurements
involved taking MUAC using a tape (MUAC Child Red/Pac-50)
and measurement of length to the nearest 1mm using an infant
length board (Infant/Child ShorrBoard®). Body weight was
measured daily to the nearest 100 g using a digital scale (Seca
813; Seca GmbH & Co.). Anthropometric z-scores were com-
puted using WHO Growth Standards(15) adjusting for the fact
that length was measured even in children <2 years, and using
the lowest weight recorded during admission, to determine
weight free from oedema.
Blood sampling
On admission, Hb was measured in venous blood collected in
heparinized vacutainer tubes (Becton Dickinson) using a Hb
201+ (HemoCue). At admission, transition and discharge,
approximately 40 µl of heparinized whole blood was applied to
a chromatography paper strip (grade 3MM; Whatman), from
which potential lipid contaminants had previously been
removed with chloroform and methanol, and treated with
antioxidants (1000 µg deferoxamine and 50 µg butylated
hydroxy toluene)(16) so that approximately 1 cm2 of the strip
was saturated with blood. At 8 and 16 weeks of follow-up,
blood samples were obtained by finger-prick and applied to
antioxidant-treated chromatography paper strip. Results from
analysis of dried blood spots collected from fingertips have
been compared with venous blood samples and found to give
substantially identical information(17) The blood spots were
allowed to dry completely at room temperature and were then
stored in a sealed container (polypropylene ‘ziplock’ bag) in a
refrigerator for up to 2 months(18) until they were shipped to
University of Waterloo, Department of Kinesiology, Canada, for
fatty acid analysis.
Whole-blood spots were chosen as the method of sample
preparation because of the simplified method for blood
collection, storage and shipment to the analytical laboratory
where samples are easily processed for analysis(17). Further-
more, whole-blood fatty acid analysis includes all lipid fractions
and is most representative of the body fatty acid status, when
compared with fatty acids in plasma, blood cells such as
erythrocytes and platelets(19,20).
Plasma was obtained from a vacutainer with citrate (Cell-
Preparation Tube; Becton Dickinson) by centrifugation at
1300–2200 g for 20min, and it was stored at −80°C until shipped
on dry ice to the University of Copenhagen, Department of
Nutrition, Exercise and Sports, Denmark, where plasma level
of C-reactive protein (CRP) was measured using the high-
sensitivity kit on a ABX Pentra 400 (Horiba, no. A11A01611 and
A11A01696).
Fatty acid analysis
Fatty acid methyl esters were prepared from the whole-blood
spots by direct trans-esterification, and they were analysed by
high-throughput GLC(21,22). Briefly, the whole-blood spot was
directly trans-esterified with the addition of 1ml of 14% boron
trifluoride in methanol (Pierce Chemicals), 300 µl of hexane and
3 µg of an internal standard (22 : 3n-3 ethyl ester; Nu-Chek Prep)
and heating at 95°C for 1 h(22). Samples were allowed to cool to
room temperature, after which water and hexane were added
(1ml each). The samples were vortexed for 1min, and then
centrifuged for 5min at 3000 rpm to separate the organic and
aqueous phases. The organic upper hexane layer containing
fatty acid methyl esters was collected, dried under a stream of N
and reconstituted in hexane. Fatty acid methyl esters were
analysed on a Varian 3900 gas chromatograph equipped with a
capillary column of 15m× 0·10mm i.d.× 0·10 μm thick film of
nitroterephthalic acid-modified polyethylene glycol (DB-FFAP
from J &W Scientific, Agilent Technologies) and hydrogen as
the carrier gas(22). Samples (1 µl) were introduced by a Varian
CP-8400 autosampler into the 250°C injector with a split ratio of
100:1. The initial temperature was 150°C, which was held for
0·25min, followed by a 35°C/min ramp to 200°C, an 8°C/min
ramp to 225°C, where it was kept for 3·2min, and then an
80°C/min ramp up to 245°C, with a 15-min hold at the end(22).
The flame ionisation detector temperature was 300°C, with air
and N make-up gas flow rates of 300 and 25ml/min, respec-
tively, and a sampling frequency of 80Hz. Peaks were identified
(thirty-four fatty acids) by comparing retention times with an
external mixed standard sample (GLC-462, Nu-Chek Prep Inc.).
Concentrations of individual fatty acids were determined
by comparing peak areas to the response of the known
concentration of the internal standard. Individual fatty acids
were also expressed as the weight percentage of total fatty acids
(FA%). Unknown peaks were included in the calculations
for weight percentage, and for each sample the identified
fatty acids accounted for over 95% of the total fatty acid
concentration. Various sums and ratios of fatty acids were
calculated from the weight percentage fatty acid data.
Statistics
Double data entry was done into Epidata, and analysis was
performed using Stata 12 (StataCorp LP). t Test and χ2 tests were
used to test for differences in means and proportions between
children with SAM and controls. Paired t test was used to
analyse change in fatty acid values at different times during
follow-up. ANCOVA in the changes of mean values from
admission was done to identify predictors of changes in PUFA
with adjustment for age and sex. P-values<0·05 were
considered statistically significant.
Results
The study recruited 120 children with a median age of
15·9 months. In all, 38% were female, 64% had oedema and
19% were HIV infected (Table 1). Control children and the
children with SAM were similar in age and sex. Other data from
the same children have been published previously(23,24).
The median duration of hospital admission was 19 d. At
admission, blood samples were obtained from 108 of the 120
recruited children with SAM. Before transition, eight children
died, five self-discharged and one was excluded because of
very low blood Hb, leaving 106 children going through
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transition, and blood samples were obtained from seventy-six
children. From transition to hospital discharge, nine children
died and thirteen self-discharged or withdrew their consent to
participate. Accordingly, eighty-three children were discharged,
and blood samples were obtained from seventy-two children.
At first follow-up 8 weeks after admission, sixty-six children
turned up, and blood samples were obtained from forty-three
children, whereas forty-nine children came for follow-up at
16 weeks after admission and blood samples were obtained
from forty-four children.
The children with SAM presented with lower LCPUFA values
at admission compared with healthy controls (Table 2). The
mean values of most SFA were lower in children with SAM until
8 weeks of follow-up (for total SFA, 44·7 FA% at transition and
44·4 FA% at discharge v. 47·7 FA% for the control children, both
P< 0·001). The proportion of most MUFA remained higher in
children with SAM throughout the follow-up period (for total
MUFA, 31·0 FA% at admission, 33·5 FA% at transition, 30·7 FA%
at discharge, 27·2 FA% at 8 weeks and 27·8 FA% at 16 weeks
follow-up v. 24·5 FA% for the controls, P< 0·001 for all time
periods except 8 weeks of follow-up, which was 0·001). The
total values of n-6 PUFA in children with SAM increased to
values similar to the controls at 8 weeks of follow-up, but it
again decreased at 16 weeks of follow-up (20·0 FA% for SAM
children v. 23·1 FA% for controls, P< 0·001). At discharge, all
individual n-6 PUFA became similar to values in the control
children, except AA, which remained lower (4·42 FA% for
SAM children compared with 5·95 FA% in controls, P< 0·001).
n-6 LCPUFA were similar to the controls by 8 weeks of
follow-up. Individual and total n-3 PUFA values decreased after
admission, apart from ALA, which was similar to healthy
children throughout follow-up. The ratio of n-6:n-3 PUFA was
lower in children with SAM than in the healthy controls
at admission (7·9 v. 8·9, P= 0·043), but it became higher in
children with SAM at all times after initiation of the treatment.
The Mead acid:AA ratio remained higher in children with SAM
throughout the entire period of treatment compared with the
control children.
Table 1. Baseline characteristics of children with severe acute malnutrition (SAM) and healthy controls*
(Medians and 25, 75 percentiles; numbers and percentages; mean values and standard deviations)
Children with SAM (n 120) Control children (n 29)
n % n % P
Age (months) 0·194
Median 15·9 16·3
25; 75 percentiles 12·6; 21·9 11·3; 24·6
Sex 0·521
Male 74 62 16 55
Female 46 38 13 45
Weight-for-height z-score† −3·4 1·4 0·8 0·9 <0·001
Weight gain at discharge (g/kg per d)† 5·8 3·2 N/A
Weight gain at 8 of weeks follow-up (g/kg per d)† 4·9 2·3 N/A
Height-for-age z-score† −3·1 1·5 −0·9 1·1 <0·001
Height gain at discharge (cm)† −0·2 1·6 N/A
Height gain at 8 weeks of follow-up (cm)† 0·8 1·4 N/A
Mother’s education 0·410
No school 6 6 1 4
Primary school 42 43 10 35
Secondary school 42 43 14 48
More than secondary school 7 7 3 10
Mother’s BMI (kg/m2)† 21·7 2·7 22·0 4·3 0·753
Breast-feeding <0·001
Breast-feeding 19 17 15 52
Not breast-feeding 92 83 14 48
Fish served in household in last 2 weeks 0·072
Yes 62 62 21 81
No 38 38 5 19
Hb (g/dl)† 9·0 2·3 10·2 1·5 0·015
Serum CRP (mg/l) 0·006
Median 19·0 10·8






Not infected 84 81
CRP, C-reactive protein; –, data not available.
* Numbers in categories may not sum up because of missing data. Data on rate of weight gain at discharge were available for eighty-two SAM children and
on weight gain at 8 weeks of follow-up on sixty-six children. Data on height gain at discharge and follow-up were available on eighty-three and sixty-five
SAM children, respectively. Data on mothers BMI were available for eighty-one SAM and seven control children. Similarly, data were available on Hb
from 112 SAM and twenty-five control children, on CRP from eighty-three SAM and twenty control children and on HIV from 104 SAM children. t Test or
χ2 tests were used to compare children with SAM and healthy controls.
†Mean and standard deviation.
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The mean changes in fatty acid values from admission to
transition, discharge and follow-up are shown in Table 3. The
mean of total SFA values decreased by 1·4 (95% CI 0·16, 2·19)
FA% during transition (P= 0·001) and by 1·6 (95% CI 0·18, 2·41)
FA% at discharge (P< 0·001). This decrease was initially
matched by an increase in the mean of total MUFA by 1·53
(95% CI 0·43, 2·63) FA% at transition (P= 0·007) but followed
by a decrease at 8 and 16 weeks of follow-up (3·6; 95% CI 2·39,
4·88 FA% and 3·2; 95% CI 2·0, 4·47 FA%, respectively,
P< 0·001). Generally, values of n-6 PUFA increased by
16 weeks of follow-up, whereas n-3 PUFA decreased.
Fig. 1 shows changes in values of PUFA classes and selected
PUFA during treatment and follow-up. LA values increased
initially at transition and discharge, remained high at 8 weeks of
follow-up and then decreased at 16 weeks. AA values reached a
nadir at transition, followed by a small increase at discharge
through to 16 weeks of follow-up. The percentage contribution
of total n-3 PUFA dropped already at transition and never
returned to admission values.
Predictors of changes in fatty acid values of children with
SAM from admission to discharge adjusted for age and sex are
summarised in Table 4. Weight gain during hospital treatment
Table 2. Fatty acid values during treatment of children with severe acute malnutrition (SAM) and healthy controls†
(Mean values and standard deviations)
Children with SAM
Admission (n 108) Transition (n 76) Discharge (n 72) 8 weeks (n 43) 16 weeks (n 44) Control children (n 24)
Fatty acid Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Saturated
12 : 0 0·20* 0·20 0·24 0·26 0·19* 0·23 0·23 0·21 0·22* 0·19 0·37 0·41
14 : 0 1·41* 0·60 1·20** 0·51 1·09** 0·67 1·42 0·80 1·33* 0·67 1·84 1·01
16 : 0 28·8* 1·8 28·9** 1·9 27·5 1·9 27·1 1·6 27·7 1·8 27·4 1·5
17 : 0 0·34** 0·09 0·25** 0·07 0·23** 0·06 0·53 1·18 0·39 0·12 0·41 0·10
18 : 0 13·0 2·3 11·4** 2·1 12·0* 2·1 13·6 2·8 13·6 2·9 13·5 1·3
20 : 0 0·27** 0·06 0·29** 0·07 0·31* 0·05 0·38* 0·09 0·36 0·07 0·34 0·06
22 : 0 0·59** 0·16 0·55** 0·17 0·66** 0·15 0·97* 0·23 0·89 0·24 0·86 0·17
23 : 0 0·10** 0·05 0·09** 0·04 0·11** 0·03 0·15* 0·04 0·15 0·05 0·17 0·05
24 : 0 0·94** 0·33 0·83** 0·30 1·02** 0·39 1·50 0·37 1·49 0·41 1·44 0·33
SFA 46·7 2·6 44·7** 3·0 44·4** 3·3 46·8 4·1 47·2 3·8 47·7 1·6
Unsaturated
16 : 1n-7 1·41 0·56 1·68 0·86 1·21 0·57 1·28 0·71 1·75 0·76 1·41 0·56
18 : 1n-7 2·10** 0·36 1·70 0·38 1·57 0·42 1·49* 0·27 1·59 0·29 1·70 0·36
18 : 1n-9 23·9** 3·1 27·9* 3·8 25·3** 3·2 21·6* 3·0 21·8** 2·9 19·0 2·5
20 : 1n-9 0·25* 0·44 0·24* 0·04 0·30 0·28 0·32** 0·05 0·27** 0·06 0·21 0·45
22 : 1n-9 0·96* 0·60 0·78 0·54 0·83 0·99 0·95** 0·36 0·87* 0·48 0·64 0·18
24 : 1n-9 1·19 0·34 1·06* 0·32 1·30 0·40 1·39 0·30 1·31 0·30 1·29 0·27
MUFA 31·0** 3·3 33·5** 3·7 30·7** 3·7 27·2* 3·1 27·8** 3·0 24·5 2·8
Mead acid (20 : 3n-9) 0·14 0·10 0·15 0·15 0·19* 0·13 0·13* 0·06 0·15* 0·07 0·11 0·06
n-6 PUFA
LA (18 : 2n-6) 10·4** 2·5 12·1** 2·0 13·7 2·5 13·9 3·0 12·4** 2·2 14·8 2·2
18 : 3n-6 0·07** 0·04 0·11 0·06 0·12 0·06 0·12 0·05 0·16* 0·08 0·12 0·07
20 : 2n-6 0·16* 0·04 0·13** 0·04 0·17 0·04 0·22* 0·06 0·18 0·04 0·18 0·04
20 : 3n-6 0·57** 0·13 0·58** 0·14 0·85 0·23 0·93 0·19 0·88 0·20 0·90 0·18
AA (20 : 4n-6) 4·67** 1·07 3·54** 0·90 4·42** 1·07 5·09* 1·17 5·07* 1·47 5·95 1·01
22 : 4n-6 0·62* 0·20 0·54** 0·17 0·72 0·23 0·90 0·27 0·84 0·34 0·77 0·33
22 : 5n-6 0·26* 0·08 0·21** 0·06 0·28 0·09 0·32 0·09 0·31 0·11 0·31 0·09
n-6 LCPUFA 6·2** 1·3 4·9** 1·1 6·3** 1·4 7·3 1·6 7·2 2·0 8·0 1·4
n-6 Fatty acids 16·8** 2·7 17·3** 2·5 20·3** 3·0 21·5 3·9 20·0** 2·6 23·1 3·0
n-3 PUFA
ALA (18 : 3n-3) 0·17 0·07 0·14* 0·05 0·17 0·11 0·16 0·07 0·20 0·11 0·19 0·11
EPA (20 : 5n-3) 0·18 0·08 0·11** 0·05 0·12** 0·05 0·12** 0·05 0·14** 0·06 0·20 0·09
22 : 5n-3 0·49 0·16 0·37** 0·13 0·41* 0·14 0·41* 0·10 0·43* 0·15 0·51 0·11
DHA (22 : 6n-3) 1·40** 0·45 1·08** 0·42 1·22** 0·51 1·06** 0·46 1·14** 0·56 1·78 0·54
n-3 LCPUFA 2·10* 0·57 1·59** 0·52 1·77** 0·64 1·64** 0·52 1·74** 0·71 2·53 0·65
n-3 Fatty acids 2·26* 0·58 1·73** 0·54 1·94** 0·68 1·80** 0·54 1·94** 0·71 2·72 0·65
PUFA 19·0** 2·9 19·0** 2·8 22·2** 3·5 23·3* 4·1 21·9** 2·9 25·8 3·2
Total fatty acid concentration 277 86 326* 118 307* 100 238 86 238 66 246 52
n-6:n-3 PUFA ratio 7·9* 2·3 10·8* 2·9 11·4* 3·3 12·9** 4·1 11·6* 4·3 8·9 2·2
Mead:AA ratio 0·03* 0·02 0·05* 0·06 0·05** 0·03 0·03* 0·01 0·03* 0·01 0·02 0·01
EPA:AA ratio 0·04 0·02 0·03 0·01 0·03* 0·01 0·03* 0·01 0·03* 0·01 0·04 0·02
22 : 5n-6:DHA ratio 0·20 0·08 0·22 0·08 0·26* 0·10 0·34** 0·14 0·31** 0·13 0·19 0·08
n, Number of children in whom information was available; LA, linoleic acid; AA, arachidonic acid; LCPUFA, long-chain PUFA; n-6:n-3 PUFA ratio, ratio of total n-6 PUFA:total
n-3 PUFA.
* P<0·05 and ** P<0·001 relative to control children. Paired t test analyses were done to test for differences in fatty acids between children with SAM at different times of follow-up
and healthy controls.
† Data for individual fatty acids and fatty acid classes are given as weight percentage of total fatty acids (FA%) and total whole-blood fatty acid concentration is expressed as
µg/100 µl.
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was associated with a higher increase in LA values (P= 0·021),
whereas an increase in height was associated with a smaller
increase in LA (P= 0·043). Breast-fed children had a smaller
increase in LA (P< 0·001) and a smaller decrease in EPA
(P= 0·043) compared with non-breast-fed children. Children
from families with recent fish intake had a smaller increase in
n-6 LCPUFA (P= 0·045) and a greater decrease in n-3 LCPUFA
values (P= 0·045). At discharge, children admitted with oedema
had a smaller decrease in n-3 DPA than those without oedema
(P= 0·038). High Hb values on admission predicted a higher
increase in LA (P= 0·028) but a smaller increase in n-6 LCPUFA
values (P= 0·042). HIV-infected children had a smaller increase
in LA values than those not infected (P= 0·001). CRP>5mg/l
predicted a more pronounced increase in LA (P= 0·049) and a
smaller decrease in n-3 LCPUFA values (P= 0·031). Children in
whom fever was reported at admission also had a greater
increase in LA values compared with those without fever
(P= 0·033).
Table 5 represents a summary of predictors of changes in
fatty acid values from admission to 8 weeks of follow-up in
children with SAM. Boys had a smaller decrease in values of n-3
LCPUFA than girls (P= 0·016). Weight gain at 8 weeks of
follow-up was associated with a higher increase in LA values
(P= 0·049), whereas an increase in height was associated with a
smaller decrease in DHA values (P= 0·036). Breast-fed children
had a smaller decrease in n-3 LCPUFA compared with non-
breast-fed children (P= 0·013). High Hb concentration was
associated with a greater decrease in DHA values (P= 0·044).
Table 3. Mean changes in fatty acid values during treatment in children with severe acute malnutrition†
(Regression coefficients (b) and 95% confidence intervals)
Transition (n 76) Discharge (n 72) 8 weeks (n 43) 16 weeks (n 44)
Fatty acid b 95% CI b 95% CI b 95% CI b 95% CI
Saturated
12 : 0 0·04 − 0·04, 0·11 0·01 −0·07, 0·08 0·05 −0·04, 0·13 0·04 −0·04, 0·13
14 : 0 − 0·14 − 0·34, 0·07 −0·21 −0·42, −0·01* 0·08 −0·15, 0·31 0·02 −0·21, 0·25
16 : 0 0·00 − 0·47, 0·47 −1·07 −1·54, −0·60** −1·35 −1·88, −0·83** −0·93 −1·46, −0·41*
17 : 0 − 0·06 − 0·16, 0·04 −0·06 −0·16, 0·04 0·14 0·03, 0·25* 0·05 −0·06, 0·16
18 : 0 − 1·14 − 1·71, −0·57** −0·68 −1·26, −0·11* 0·51 −0·14, 1·15 0·49 −0·15, 1·13
20 : 0 0·01 − 0·00, 0·03 0·03 0·02, 0·05** 0·08 0·06, 0·10** 0·07 0·05, 0·09**
22 : 0 − 0·01 − 0·06, 0·04 0·07 0·02, 0·12* 0·29 0·23, 0·35** 0·24 0·18, 0·30**
23 : 0 − 0·00 − 0·02, 0·01 0·01 −0·00, 0·02 0·04 0·03, 0·06** 0·05 0·03, 0·06**
24 : 0 − 0·06 − 0·16, 0·05 0·09 −0·01, 0·19 0·44 0·33, 0·56** 0·44 0·32, 0·55**
SFA − 1·40 − 2·19, −0·61* −1·61 −2·41, −0·81** 0·27 −0·62, 1·17 0·50 −0·40, 1·39
Unsaturated
16 : 1n-7 − 0·64 − 0·83, −0·44** −0·99 −1·19, −0·79** −0·92 −1·14, −0·70** −0·62 −0·84, −0·40**
18 : 1n-7 − 0·33 − 0·43, −0·24** −0·43 −0·52, −0·33** −0·46 −0·57, −0·36** −0·40 −0·51, −0·29**
18 : 1n-9 2·77 1·74, 3·79** 0·68 −0·36, 1·71 −2·37 −3·53, −1·21** −2·20 −3·36, −1·05**
20 : 1n-9 − 0·00 − 0·04, 0·03 0·04 0·01, 0·07* 0·04 0·00, 0·08* 0·01 −0·02, 0·05
22 : 1n-9 − 0·16 − 0·31, −0·01* −0·12 −0·27, 0·03 −0·06 −0·23, 0·11 −0·12 −0·29, 0·06
24 : 1n-9 − 0·09 − 0·18, −0·01* 0·09 −0·00, 0·17 0·14 0·05, 0·24* 0·09 −0·00, 0·19
MUFA 1·53 0·43, 2·63* −0·72 −1·84, 0·39 −3·63 −4·88, −2·39** −3·23 −4·47, −2·00**
Mead acid (20 : 3n-9) 0·01 − 0·02, 0·03 0·03 0·01, 0·06* −0·01 −0·04, 0·03 −0·00 −0·03, 0·03
n-6 PUFA
LA (18 : 2n-6) 1·59 0·91, 2·28** 2·77 2·07, 3·46** 3·01 2·23, 3·78** 2·10 1·33, 2·87**
18 : 3n-6 0·04 0·02, 0·05** 0·04 0·02, 0·05** 0·04 0·03, 0·06** 0·07 0·05, 0·08**
20 : 2n-6 − 0·02 − 0·03, −0·01* 0·01 −0·00, 0·02 0·04 0·03, 0·06** 0·02 0·01, 0·04*
20 : 3n-6 0·03 − 0·02, 0·08 0·23 0·18, 0·29** 0·29 0·23, 0·35** 0·26 0·20, 0·32**
AA (20 : 4n-6) − 0·79 − 1·12, −0·46** −0·10 −0·44, 0·23 0·50 0·12, 0·87* 0·48 0·11, 0·85*
22 : 4n-6 − 0·06 − 0·13, 0·01 0·08 0·01, 0·15* 0·21 0·13, 0·28** 0·16 0·09, 0·24**
22 : 5n-6 − 0·03 − 0·06, −0·01* 0·02 −0·00, 0·04 0·05 0·02, 0·07** 0·04 0·01, 0·07*
n-6 LCPUFA − 0·85 − 1·28, −0·43** 0·23 −0·20, 0·66 1·05 0·57, 1·53** 0·95 0·47, 1·43**
n-6 Fatty acids 0·76 − 0·15, 1·67 3·04 2·12, 3·96** 4·14 3·11, 5·17** 3·13 2·10, 4·16**
n-3 PUFA
ALA (18 : 3n-3) − 0·02 − 0·04, 0·01 0·01 −0·02, 0·03 0·00 −0·03, 0·03 0·03 0·00, 0·05*
EPA (20 : 5n-3) − 0·05 − 0·07, −0·03** −0·04 −0·06, −0·02** −0·04 −0·06, −0·01* −0·03 −0·05, −0·01*
22 : 5n-3 − 0·09 − 0·13, −0·05** −0·06 −0·10, −0·02* −0·05 −0·09, −0·00* −0·04 −0·08, 0·00
DHA (22 : 6n-3) − 0·22 − 0·36, −0·07* −0·11 −0·26, 0·04 −0·15 −0·31, 0·02 −0·10 −0·26, 0·06
n-3 LCPUFA − 0·36 − 0·54, −0·18** −0·21 −0·40, −0·03* −0·22 −0·42, −0·01* −0·16 −0·36, 0·05
n-3 Fatty acids − 0·38 − 0·56, −0·19** −0·21 −0·39, −0·02* −0·22 −0·43, −0·01* −0·13 −0·34, 0·08
PUFA 0·38 − 0·63, 1·39 2·84 1·81, 3·86** 3·93 2·78, 5·07** 3·00 1·86, 4·14**
Total fatty acid concentration (µg/100 µl) 35·5 12·5, 58·5* 20·6 − 2·6, 43·9 −29·9 −55·1,−3·9* −30·1 −56·0,−4·2*
n-6:n-3 PUFA ratio 2·3 1·5, 3·1** 2·7 1·9, 3·5** 3·4 2·5, 4·3** 2·6 1·7, 3·5**
Mead acid:AA ratio 0·01 0·00, 0·02* 0·01 0·00, 0·02* −0·00 −0·01, 0·01 −0·00 −0·01, 0·01
EPA:AA ratio − 0·01 − 0·01, −0·00** −0·01 −0·01, −0·01** −0·01 −0·02, −0·01** −0·01 −0·01, −0·01**
22:5n-6:DHA ratio 0·01 − 0·02, 0·04 0·04 0·02, 0·07* 0·09 0·06, 0·12** 0·07 0·04, 0·10**
n, Number of children in whom information was available; LA, linoleic acid; AA, arachidonic acid; LCPUFA, long-chain PUFA; n-6:n-3 PUFA ratio, ratio of total n-6 PUFA:total
n-3 PUFA.
* P<0·05 and ** P<0·001 relative to admission values.
† Paired t test analyses were done to test for differences in fatty acids at different times of follow-up compared with admission values.
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Children with oral thrush had a smaller increase in n-6 LCPUFA
(P= 0·035), whereas those who had NG tube feeding in the first
2 d of admission had a smaller increase in n-6 LCPUFA
(P= 0·027) and a greater decrease in n-3 LCPUFA (P= 0·047).
Children who died or were otherwise lost to follow-up had
slightly higher CRP values on admission than those who
remained in the study (P= 0·068), and were not different with
respect to age, sex, breast-feeding, nutritional status and
admission Hb concentration (data not shown). Admission
values of LA, ALA, AA and DHA were also not different in
children who were followed up and those not followed up.
Discussion
This study shows that in-hospital treatment of SAM with con-
ventional F-75 and F-100 was associated with decreases in
whole-blood n-3 LCPUFA proportions at discharge. As we
demonstrate that the children with SAM already at admission
had significantly lower proportions of LCPUFA than controls,
this is a cause for concern. There could be many reasons for


























































Fig. 1. Trend of changes in fatty acid values during treatment. (a) ,
linoleic acid; , arachidonic acid; , total n-6 PUFA; , total
PUFA. (b) α-Linolenic acid; , DHA; , total n-3 PUFA .
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low levels of ALA (0·25 percentage of energy intake (%E) and
0·3%E, respectively). Another reason may be that F-75 and
F-100 contain only ALA and LA and thus require an ability in the
child to convert these into the functionally important LCPUFA,
AA, EPA and DHA. Several studies suggest a compromised
ability to elongate and desaturate in children with SAM(5,25).
Most recently, a study demonstrated that Kenyan children could
only improve their DHA status when fish oil was added directly
to the feeds, not with extra ALA(8). Another important obser-
vation in this study was that the children with SAM had per-
sistent lower whole-blood levels of PUFA, especially of n-3
PUFA, during recovery compared with healthy control children.
The treatment resulted in normalisation in the percentage
contribution of LA at discharge, but LA values had decreased to
less than the control values again by 16 weeks of follow-up. The
mean values of AA initially reduced at transition, but then
increased during treatment, although it remained lower than
that of control children at the end of recovery. These data agree
with Koletzko et al.(25), who also found increasing levels of LA
in Nigerian children with SAM and decreasing AA levels during
treatment. In the current study, DHA values decreased during
the entire follow-up period. Similarly, other studies have found
a lack of increases in DHA values during dietary intervention of
malnourished children(6,25).
The decrease in n-3 LCPUFA was less pronounced in breast-
fed children. Breastmilk is a recognised source of n-3 LCPUFA,
the composition being dependent on maternal nutrition(26,27).
Children from families with recent fish intake had a smaller
increase in n-6 LCPUFA and a greater decrease in n-3 LCPUFA
during treatment. This may imply that they had better LCPUFA
levels at admission probably because of a better supply of
LCPUFA than the therapeutic feeds given at the hospital.
Furthermore, the changes in LCPUFA levels ceased to be
significant at 8 weeks of follow-up, which may be related to a
gradual return to a home diet. This emphasizes a need to revisit
the PUFA content in therapeutic feeds.
Children with lower Hb at admission had a less pronounced
increase in LA at discharge and a higher increase in total n-6
LCPUFA. We anticipate that there may be a build-up of Hb and
erythrocytes during rehabilitation. It could be speculated that
the increased dietary supply of LA during treatment may have
been converted to n-6 LCPUFA for deposition in the erythrocyte
cell membrane as SAM subsides and growth and build of tissues
restarts. Hence, the increase in whole-blood n-6 LCPUFA may
be more pronounced in anaemic children in an effort to restore
Hb levels. Children infected with HIV also had a smaller
increase in LA by the time of discharge than HIV-negative
children. Low levels of LA have previously been described in
HIV-infected children, and they have been attributed to high
PUFA turn-over(28).
A number of children with SAM have infections when first
admitted(29,30), and they all receive empirical antibiotics
according to guidelines(10). Infections in general, as indicated
by CRP>5mg/l at admission, predicted a more pronounced
increase in whole-blood LA values and a smaller decrease in the
level of n-3 LCPUFA at discharge, but the association ceased to
be significant by 8 weeks of follow-up. When infections are
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decrease, which could explain this observed increase in LA
values. In addition, as inflammatory processes subside, it is
plausible that less n-3 LCPUFA is catabolised for the production
of anti-inflammatory mediators, which may explain the
observed smaller decrease in n-3 LCPUFA. However, children
with oral thrush at admission and those who had been fed
through the NG tube within the first 2 d of admission had a
smaller increase in values of AA and total n-6 LCPUFA at
8 weeks of follow-up and NG tube fed children also had a larger
decrease in DHA and total n-3 LCPUFA values at 8 weeks of
follow-up. Oral thrush is a fungal infection of oral cavity
mucous membrane, and children who were NG tube fed were
quite sick and prone to severe infections. All these processes
could perhaps lead to marked derangement in metabolism,
increased production of inflammatory eicosanoids and thus
contribute to the use of LCPUFA.
One limitation to this study is its observational nature limiting
causal inference of the decreased values of LCPUFA in children
with SAM. Second, as the aim was to explore predictors of
changes in essential fatty acids, a large number of tests were
performed, which may have increased the risk of chance findings.
Furthermore, we had a high loss of patients, particularly at
8 and 16 weeks of follow-up, and as many of these dropouts
were because of children dying, it is likely that the children lost
were sicker than those who remained in the study. However,
when assessing changes over time, we only compared the
children for whom data were available at both admission and
later. The high loss to follow-up of children reduces the statis-
tical power of our study. Besides loosing children in follow-up,
it was not possible to get blood samples from all the children
we were able to follow-up. In addition, whole-blood fatty acid
analysis limits our ability to determine fatty acid distribution in
the different lipid classes as compared with detailed sub ana-
lyses. Having said this, our results are in line with previous
results. Another limitation may be that control children were
only studied once, whereas study children were followed up
over time. It is possible that some change would also have
occurred in the fatty acid proportions in control children over
time, because of the seasonal change in diet. However, the
change in study children during in-patient treatment is unlikely
to be explained by seasonal variation, as the diet was standar-
dised, with almost no local foods included.
There is an increasing concern whether therapeutic feeds are
able to correct essential fatty acid status of children recovering
from SAM(31). As the children were treated according to the
Uganda Ministry of Health guidelines, PUFA levels at transition
reflect the impact of F-75, at discharge the impact of F-100 and
at 8 weeks of follow-up the impact of RUTF. During recovery,
energy- and nutrient-dense foods are encouraged at home to
achieve good catch-up growth; hence, 16 weeks of follow-up
reflects the impact of the home diet. Thus, the low levels of
particularly n-3 LCPUFA at discharge and 8 weeks of recovery
from SAM suggest that the F-100 and RUTF cannot correct pre-
existing compromised essential fatty acid status. Furthermore,
the ratio of n-6:n-3 PUFA at admission was lower in children
with SAM, but then became higher than in the healthy controls
following treatment, thus reflecting an overall pronounced lack
of n-3 PUFA in all therapeutic diets. For RUTF, WHO and the
World Food Programme recommend a fat content of 45–60%E,
of which 3–10%E should come from n-6 fatty acids and
0·3–2·5%E from n-3 fatty acids(11). F-100 follows these same
specifications for essential fatty acids. Standard RUTF contains
ALA corresponding to 0·3–2·5%E and 3–10%E LA. Both RUTF
and F-100 meet the WHO minimum recommendations for ALA
and LA and none of the recommendations mention anything
about content of LCPUFA relative to the shorter-chain PUFA in
therapeutic diets.
Hsieh et al.(9) demonstrated a worsening of n-3 LCPUFA
status in children with uncomplicated SAM after 4 weeks of
treatment with conventional RUTF compared with children
treated with HO-RUTF with decreased LA contents. Further-
more, Jones et al.(8) noted that provision of RUTF with elevated
ALA had minimal impact on n-6 and n-3 PUFA status, but that
addition of fish oil was associated with marked increases in n-3
LCPUFA. HO-RUTF on the other hand led to relative increases
of +29% and +87% for DHA and EPA, respectively(9). The
strategy of increasing oleic acid and decreasing LA to a 1:1 ratio
with ALA may therefore be a promising way to improve the n-3
LCPUFA status of children treated for SAM without having to
add fish oil to the therapeutic feeds.
Conclusion
Whole-blood n-6 PUFA proportions increased from admission
over discharge to follow-up, except for AA, whereas n-3
LCPUFA proportions of EPA and DHA decreased during
in-hospital treatment. Furthermore, both n-3 and n-6 PUFA
proportions remained lower than those of the healthy controls
at the end of treatment. Thus, the current recommended
therapeutic feeds for rehabilitating children with SAM are not
able to correct their whole-blood LCPUFA compromised status.
Although there were significant increases in n-6 LCPUFA values
during treatment, the decreases in n-3 LCPUFA and AA
proportions from admission to discharge pose particular
concern, as AA and DHA play important functional roles in the
brain, retina and immune system. F-75 and F-100 formulations
with higher n-3 PUFA contents to decrease n-6:n-3 ratio and
preformed LCPUFA may need to be considered in therapeutic
diets for children with SAM.
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